CY1123041T1 - Συνδυασμος κανρενοατης και εξενατιδης - Google Patents
Συνδυασμος κανρενοατης και εξενατιδηςInfo
- Publication number
- CY1123041T1 CY1123041T1 CY20201100511T CY201100511T CY1123041T1 CY 1123041 T1 CY1123041 T1 CY 1123041T1 CY 20201100511 T CY20201100511 T CY 20201100511T CY 201100511 T CY201100511 T CY 201100511T CY 1123041 T1 CY1123041 T1 CY 1123041T1
- Authority
- CY
- Cyprus
- Prior art keywords
- combination
- analog
- functional derivative
- exenatide
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει συνδυασμό που περιλαμβάνει τουλάχιστον δύο από τα ακόλουθα: (i) διαμορφωτή ινσουλίνης, (ii) ανοσοκατασταλτικό παράγοντα και (iii) ανταγωνιστή αλδοστερόνης, για παράδειγμα συνδυασμό που περιλαμβάνει τουλάχιστον δύο από (i) εξενατίδη, ή λειτουργικό παράγωγο ή ανάλογο αυτής, ή αποδεκτό από φαρμακευτική άποψη άλας αυτών (ii) κυκλοσπορίνη, ή λειτουργικό παράγωγο ή ανάλογο αυτής, ή αποδεκτό από φαρμακευτική άποψη άλας αυτών• και (iii) κανρενοϊκό κάλιο, ή λειτουργικό παράγωγο ή ανάλογο αυτού. Οι εν λόγω συνδυασμοί είναι κατάλληλη για καρδιοπροστασία και για την αγωγή και/ή πρόληψη ισχαιμίας και/ή τραυματισμού επαναιμάτωσης. Περαιτέρω πτυχές της εφεύρεσης σχετίζονται με φαρμακευτικά προϊόντα και φαρμακευτικές συνθέσεις που περιλαμβάνουν τους εν λόγω συνδυασμούς σύμφωνα με την εφεύρεση, και μεθόδους αγωγής με χρήση αυτών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20150100486 | 2015-11-06 | ||
| PCT/IB2016/001582 WO2017077378A1 (en) | 2015-11-06 | 2016-11-04 | Combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123041T1 true CY1123041T1 (el) | 2021-10-29 |
Family
ID=57421900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100511T CY1123041T1 (el) | 2015-11-06 | 2020-06-05 | Συνδυασμος κανρενοατης και εξενατιδης |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10172914B2 (el) |
| EP (1) | EP3370756B1 (el) |
| JP (1) | JP6928611B2 (el) |
| CN (1) | CN108472333B (el) |
| CY (1) | CY1123041T1 (el) |
| DK (1) | DK3370756T3 (el) |
| ES (1) | ES2791301T3 (el) |
| HR (1) | HRP20200845T1 (el) |
| HU (1) | HUE049732T2 (el) |
| LT (1) | LT3370756T (el) |
| ME (1) | ME03734B (el) |
| PL (1) | PL3370756T3 (el) |
| PT (1) | PT3370756T (el) |
| RS (1) | RS60354B1 (el) |
| SI (1) | SI3370756T1 (el) |
| WO (1) | WO2017077378A1 (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114423461A (zh) * | 2019-07-09 | 2022-04-29 | 杰尼西斯制药有限公司 | 组合 |
| WO2023026247A1 (en) | 2021-08-27 | 2023-03-02 | Genesis Pharma Sa | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
| CA2625646A1 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| JP2012517977A (ja) * | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| CN101810859A (zh) * | 2010-02-09 | 2010-08-25 | 王丽燕 | 包含苯胺衍生物的药物组合物 |
| EP2768856A4 (en) | 2011-10-18 | 2015-05-27 | Prolynx Llc | PEG CONJUGATES OF EXENATIDE |
| CN103087139B (zh) * | 2011-11-08 | 2016-08-03 | 中国科学院上海药物研究所 | 一种坎利酮衍生物类甾体化合物、其制备方法及其在制备依普利酮中的用途 |
-
2016
- 2016-11-04 EP EP16802132.7A patent/EP3370756B1/en active Active
- 2016-11-04 SI SI201630797T patent/SI3370756T1/sl unknown
- 2016-11-04 HU HUE16802132A patent/HUE049732T2/hu unknown
- 2016-11-04 DK DK16802132.7T patent/DK3370756T3/da active
- 2016-11-04 PT PT168021327T patent/PT3370756T/pt unknown
- 2016-11-04 JP JP2018541582A patent/JP6928611B2/ja active Active
- 2016-11-04 ES ES16802132T patent/ES2791301T3/es active Active
- 2016-11-04 ME MEP-2020-107A patent/ME03734B/me unknown
- 2016-11-04 CN CN201680078080.XA patent/CN108472333B/zh active Active
- 2016-11-04 PL PL16802132T patent/PL3370756T3/pl unknown
- 2016-11-04 LT LTEP16802132.7T patent/LT3370756T/lt unknown
- 2016-11-04 RS RS20200614A patent/RS60354B1/sr unknown
- 2016-11-04 WO PCT/IB2016/001582 patent/WO2017077378A1/en active Application Filing
-
2017
- 2017-08-09 US US15/672,841 patent/US10172914B2/en active Active
-
2018
- 2018-11-27 US US16/201,703 patent/US20190290721A1/en active Pending
-
2020
- 2020-05-26 HR HRP20200845TT patent/HRP20200845T1/hr unknown
- 2020-06-05 CY CY20201100511T patent/CY1123041T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018537522A (ja) | 2018-12-20 |
| SI3370756T1 (sl) | 2020-08-31 |
| PL3370756T3 (pl) | 2020-10-19 |
| CN108472333B (zh) | 2023-05-12 |
| JP6928611B2 (ja) | 2021-09-01 |
| CN108472333A (zh) | 2018-08-31 |
| US20170333519A1 (en) | 2017-11-23 |
| ES2791301T3 (es) | 2020-11-03 |
| RS60354B1 (sr) | 2020-07-31 |
| US20190290721A1 (en) | 2019-09-26 |
| PT3370756T (pt) | 2020-05-18 |
| WO2017077378A1 (en) | 2017-05-11 |
| EP3370756B1 (en) | 2020-04-08 |
| EP3370756A1 (en) | 2018-09-12 |
| US10172914B2 (en) | 2019-01-08 |
| ME03734B (me) | 2021-01-20 |
| HRP20200845T1 (hr) | 2020-08-07 |
| LT3370756T (lt) | 2020-07-10 |
| HUE049732T2 (hu) | 2020-10-28 |
| DK3370756T3 (da) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37182A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| CR20190446A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NZ739250A (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| UY37741A (es) | Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue | |
| CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
| CL2018002729A1 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| CY1121326T1 (el) | Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| UY36339A (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| MY181181A (en) | Fgf21 derivatives and uses thereof | |
| BR112018071370A2 (pt) | composições farmacêuticas orais de mesalazina | |
| CY1123041T1 (el) | Συνδυασμος κανρενοατης και εξενατιδης | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
| CY1121063T1 (el) | Αναστολεις της συνθασης της αλδοστερονης | |
| TR201901977T4 (tr) | Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| WO2016172269A3 (en) | Insulin analogs having shortened b chain peptides and associated methods | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. |